144 related articles for article (PubMed ID: 34713772)
1. Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.
Duff K; Suhrie KR; Hammers DB; Dixon AM; King JB; Koppelmans V; Hoffman JM
Clin Neuropsychol; 2023 Jan; 37(1):157-173. PubMed ID: 34713772
[TBL] [Abstract][Full Text] [Related]
2. Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.
Suhrie KR; Hammers DB; Porter SM; Dixon AM; King JB; Anderson JS; Duff K; Hoffman JM
J Clin Exp Neuropsychol; 2021 Nov; 43(9):861-878. PubMed ID: 35019815
[TBL] [Abstract][Full Text] [Related]
3. Change on the Repeatable Battery for the Assessment of Neuropsychological Status and its relationship to brain amyloid.
Duff K; Dixon AM; Embree L; Hoffman JM
J Clin Exp Neuropsychol; 2023 Mar; 45(2):105-117. PubMed ID: 37224404
[TBL] [Abstract][Full Text] [Related]
4. Recall and recognition subtests of the repeatable battery for the assessment of neuropsychological status and their relationship to biomarkers of Alzheimer's disease.
Euler MJ; Duff K; King JB; Hoffman JM
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2023; 30(6):885-902. PubMed ID: 36110031
[TBL] [Abstract][Full Text] [Related]
5. The Quick Dementia Rating System and Its Relationship to Biomarkers of Alzheimer's Disease and Neuropsychological Performance.
Duff K; Wan L; Levine DA; Giordani B; Fowler NR; Fagerlin A; King JB; Hoffman JM
Dement Geriatr Cogn Disord; 2022; 51(3):214-220. PubMed ID: 35477163
[TBL] [Abstract][Full Text] [Related]
6. Relationship between
Hammers DB; Atkinson TJ; Dalley BC; Suhrie KR; Beardmore BE; Burrell LD; Horn KP; Rasmussen KM; Foster NL; Duff K; Hoffman JM
Clin Neuropsychol; 2017 Apr; 31(3):531-543. PubMed ID: 28077020
[TBL] [Abstract][Full Text] [Related]
7. Recognition subtests for the Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary data in cognitively intact older adults, amnestic Mild Cognitive Impairment, and Alzheimer's disease.
Duff K; Suhrie KR; Dalley BCA; Porter SM; Dixon AM
Clin Neuropsychol; 2021 Nov; 35(8):1415-1425. PubMed ID: 32883179
[No Abstract] [Full Text] [Related]
8. Relationship between a novel learning slope metric and Alzheimer's disease biomarkers.
Hammers DB; Suhrie K; Dixon A; Gradwohl BD; Archibald ZG; King JB; Spencer RJ; Duff K; Hoffman JM
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2022 Sep; 29(5):799-819. PubMed ID: 33952156
[TBL] [Abstract][Full Text] [Related]
9. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
[TBL] [Abstract][Full Text] [Related]
10. Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.
Duff K; Hammers DB; Koppelmans V; King JB; Hoffman JM
J Alzheimers Dis; 2024; 99(1):321-332. PubMed ID: 38669544
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of memory subtests and learning slopes from the ADAS-Cog to distinguish along the continuum of the NIA-AA Research Framework for Alzheimer's Disease.
Hammers DB; Kostadinova RV; Spencer RJ; Ikanga JN; Unverzagt FW; Risacher SL; Apostolova LG;
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2023; 30(6):866-884. PubMed ID: 36074015
[TBL] [Abstract][Full Text] [Related]
12. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
[TBL] [Abstract][Full Text] [Related]
14. Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly.
Dhilla Albers A; Asafu-Adjei J; Delaney MK; Kelly KE; Gomez-Isla T; Blacker D; Johnson KA; Sperling RA; Hyman BT; Betensky RA; Hastings L; Albers MW
Ann Neurol; 2016 Dec; 80(6):846-857. PubMed ID: 27696605
[TBL] [Abstract][Full Text] [Related]
15. APOE-ε4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies.
Saeed U; Mirza SS; MacIntosh BJ; Herrmann N; Keith J; Ramirez J; Nestor SM; Yu Q; Knight J; Swardfager W; Potkin SG; Rogaeva E; St George-Hyslop P; Black SE; Masellis M
Alzheimers Dement; 2018 Sep; 14(9):1137-1147. PubMed ID: 29782824
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial.
Chen GQ; Sheng C; Li YX; Yu Y; Wang XN; Sun Y; Li HY; Li XY; Xie YY; Han Y
BMC Neurol; 2016 May; 16():64. PubMed ID: 27176479
[TBL] [Abstract][Full Text] [Related]
17. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
18. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease.
Karantzoulis S; Novitski J; Gold M; Randolph C
Arch Clin Neuropsychol; 2013 Dec; 28(8):837-44. PubMed ID: 23867976
[TBL] [Abstract][Full Text] [Related]
19. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
[TBL] [Abstract][Full Text] [Related]
20. RBANS memory percentage retention: No evidence of incremental validity beyond RBANS scores for diagnostic classification of mild cognitive impairment and dementia and for prediction of daily function.
Jodouin KA; O'Connell ME; Morgan DG
Appl Neuropsychol Adult; 2017; 24(5):420-428. PubMed ID: 27282346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
